NYSDA Publications

NIH Launches Clinical Trial of Hyperimmune Intravenous Immunoglobulin Plus Remdesivir for COVID-19 Treatment

The National Institutes of Health (NIH) has launched a clinical trial of hyperimmune intravenous immunoglobulin plus remdesivir as a treatment for the novel coronavirus (COVID-19).  To read the NIH announcement and summary of the launch of a clinical trial of hyperimmune intravenous immunoglobulin plus remdesivir as a treatment for COVID-19, use the link below.
https://www.nih.gov/news-events/news-releases/nih-clinical-trial-testing-hyperimmune-intravenous-immunoglobulin-plus-remdesivir-treat-covid-19-begins
"Local":"NewYorkCountyNY"